FrieslandCampina’s human milk oligosaccharide ingredient obtains EU approval and GRAS status

By Jim Cornall contact

- Last updated on GMT

FrieslandCampina DOMO's 2’-FL is the result of a global partnership with the US-based company Glycosyn.
FrieslandCampina DOMO's 2’-FL is the result of a global partnership with the US-based company Glycosyn.

Related tags: Human milk, Milk, Infant formula, Frieslandcampina

FrieslandCampina DOMO’s new Human Milk Oligosaccharide (HMO) ingredient, 2’-fucosyllactose (2’-FL), has been officially certified to be used in infant formula in both European and US markets.

The ingredient has received EU novel food approval and achieved GRAS (Generally Recognised as Safe) status from the Food and Drug Administration (FDA) in the US.

FrieslandCampina said both approvals are important as the company looks to launch its first human milk oligosaccharide by the end of the year.

More than 200 varieties

HMOs are non-digestible carbohydrates and are the third most abundant component in human milk after lactose and fat. More than 200 different varieties have currently been identified in human milk, of which 2’-FL is the most prevalent.

Recent clinical trials have suggested that 2’-FL plays a key role in protecting and promoting the health of newborn infants, particularly in respect to the immune system, and have shown that the addition of 2’-FL to infant formula is safe and well tolerated.

FrieslandCampina DOMO always advocates breast feeding, however, when this is not possible, the addition of HMOs to infant formula products marks a significant development in supporting early nutrition.

Created through partnership

2’-FL is the result of a global partnership between FrieslandCampina DOMO and the US-based company Glycosyn.

FrieslandCampina DOMO’s 2’-FL ingredient, which will be marketed under the brand name Aequival, is the first product in a range of HMOs that will be commercially available from the company in the foreseeable future.

Italian plant

In addition, a dedicated 2’-FL plant is being built in Italy, allowing large-scale production to take place by the end of this year. Available for the global market, 2’-FL has been developed using Glycosyn’s patented technology.

Godert Zijlstra, business development director HMOs, said, “By the end of 2018, our first HMO, Aequival 2’-FL, will be commercially available.”

He said the company will be formulating and launching a broad range of HMOs over the next few years.

“After decades of experience in infant nutrition and oligosaccharides, we have embarked on a new and exciting time in the development of breakthrough innovations for our industry,”​ Zijlstra said.

Related products

show more

Customized Fill Release in Gelatine Soft Capsules

Customized Fill Release in Gelatine Soft Capsules

Gelita AG | 21-May-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Making Health Claims on Infant Nutrition

Making Health Claims on Infant Nutrition

KGK Science, Inc. | 01-May-2018 | Technical / White Paper

The market for infant formula has expanded over the past decade and competition is high amongst leading manufacturers to make claims that differentiate...

Omegavie® DHA algae Capsules

Omegavie® DHA algae Capsules

POLARIS | 05-Mar-2018 | Application Note

Omegavie® DHA algae capsules is a real opportunity to consume high-performing Omega-3 DHA 100% vegan, natural, sustainable, GMO- and allergen-free. Designed...

Related suppliers

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Products

View more

Webinars